Breaking News

Page
12345›»

HTG Introduces New Product to Measure MicroRNA

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system...

Tuesday, January 06, 2009 Source: BUSINESS WIRE

Leading Researchers Establish FORMA Therapeutics to Integrate Transformative Biology and Chemistry to Address Challenging Targets and Develop Breakthrough Oncology Drugs

FORMA Therapeutics announced today its debut as an integrated, global drug discovery company...

Tuesday, January 06, 2009 Source: BUSINESS WIRE

arGentis Receives Favorable Opinion for European Orphan Drug Designation

arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency’s...

Tuesday, January 06, 2009 Source: BUSINESS WIRE

Seegene Receives Patent for Use of Multiplex PCR for Haplotyping Experiments

Seegene Inc. received international patent protection for the use of multiplex...

Tuesday, January 06, 2009 Source: VerusMed

Researchers Develop Real-Time, One-Step RT-PCR Assay to Detection Chandipura Virus

Use of a real-time, one-step RT-PCR (reverse transcriptase polymerase chain...

Tuesday, January 06, 2009 Source: VerusMed

Galapagos NV Selects Pre-Clinical Candidate Drug for Cachexia

Galapagos NV (Euronext: GLPG) announced today that it has selected a candidate...

Tuesday, January 06, 2009 Source: Marketwire

Cylene Pharmaceuticals, Inc. Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical...

Tuesday, January 06, 2009 Source: PRNewswire

Discovery Labs' Surfaxin(r) Phase 2 BPD Clinical Trial Results Published in Pediatrics

Discovery Laboratories, Inc. (Nasdaq:DSCO) announces the publication of results...

Tuesday, January 06, 2009 Source: GLOBE NEWSWIRE

Immutep S.A. Announces Positive Interim Results in Phase I/II Chemoimmunotherapy Trial in Breast Cancer

Orsay, France, January 5th, 2009, Immutep S.A. announced today interim results...

Tuesday, January 06, 2009 Source: BioSpace.com

DOR BioPharma, Inc. (DORB) Receives SPA Clearance From the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB)...

Tuesday, January 06, 2009 Source: Marketwire
Page
12345›»

News Search

Search News By Keywords

News Sections

New Technologies

FluoView® FV10i
from Olympus
3D Track Objects
from Molecular Devices, now a part...
More New Technologies
advertisement
Advertisement (image not found)

Email Newsletter Sign-Up

Stay updated on the latest technologies and news with Biocompare's newsletters
(See samples here)









 Select All

Privacy Policy | Manage Subscriptions

Loading

Loading